prdm10 Antibody

What is PRDM10 and why is it important in research?

PRDM10 (PR Domain Containing 10) belongs to the PRDM family of proteins, which contain a PR (PRDI-BF1 and RIZ homology) domain similar to the catalytic motif of histone methyltransferases. PRDM10 functions as a critical transcriptional regulator involved in chromatin remodeling and tissue differentiation . Recent research has revealed its importance in embryonic development, particularly in the oocyte-to-embryo transition, and its potential role in pathogenesis of certain cancers and genetic disorders . Its ability to regulate gene expression through direct binding to specific DNA motifs makes it a valuable research target in developmental biology, cancer research, and genetic disease studies.

How do I select the appropriate PRDM10 antibody for my experimental needs?

Selection should be guided by your specific application and target species. Consider the following factors:

For cross-species reactivity, examine validation data specific to your target species, as PRDM10 antibodies vary in their reactivity to human, mouse, and other models . Always review the validation data in applications similar to your intended use.

What expression patterns of PRDM10 should I expect in different tissue types?

PRDM10 expression varies significantly across developmental stages and tissue types. During mouse embryonic development, PRDM10 expression is initially concentrated in mesodermal and neural crest populations (E8.5), later shifting to mesoderm-derived tissues such as somites and neural crest-derived populations including the facial skeleton (E13.5-E16.5) . This pattern is maintained into adulthood, suggesting PRDM10's role in tissue differentiation . In humans, PRDM10 expression appears in various tissue types, with notable expression in reproductive tissues, particularly in oocytes, where it plays a crucial role in early embryogenesis . When designing experiments, consider that expression patterns may vary across species and developmental stages.

How can I optimize immunoprecipitation protocols specifically for PRDM10?

Optimizing PRDM10 immunoprecipitation requires addressing several technical challenges due to its nuclear localization and size (131 kDa calculated, observed at 120-150 kDa):

• Lysis buffer optimization: Use a nuclear extraction protocol with HEPES buffer (pH 7.5-7.9) containing 150-300 mM NaCl, 1% NP-40 or Triton X-100, and protease inhibitors.

• Antibody selection: Choose antibodies validated for IP applications, such as the rabbit polyclonal antibody (23827-1-AP) that has demonstrated success in mouse testis tissue .

• Antibody amount optimization: Start with 0.5-4.0 μg antibody per 1.0-3.0 mg of total protein lysate , then adjust based on results.

• Pre-clearing strategy: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Cross-linking consideration: For detecting PRDM10's DNA-binding interactions, consider formaldehyde cross-linking (0.1-0.5%) before cell lysis.

• Washing conditions: Perform stringent washes (at least 4-5 times) with buffers containing 150-300 mM salt to minimize non-specific interactions.

For co-IP experiments investigating PRDM10's interaction partners, gentler lysis conditions may be required to preserve protein-protein interactions.

What are the key considerations when designing ChIP experiments to study PRDM10 binding to the FLCN promoter?

When investigating PRDM10 binding to the FLCN promoter through ChIP experiments, consider these critical factors:

• Primer design: Design multiple primer sets surrounding the predicted PRDM10 binding motif (GGTGGTACGGCTCA) . Consider both the experimental and control primer sets as demonstrated in previous research:

• Cross-linking optimization: PRDM10 is a transcription factor with zinc-finger domains; use 1% formaldehyde for 10 minutes at room temperature as a starting point.

• Sonication protocol: Optimize to achieve chromatin fragments of 200-500 bp, typically 10-15 cycles (30s on/30s off) at medium power.

• Antibody selection: Use ChIP-validated antibodies specifically targeting PRDM10 DNA-binding domains.

• Controls: Include:

  • Input control (pre-immunoprecipitated chromatin)

  • IgG negative control

  • Positive control (known PRDM10 binding site)

  • Wildtype vs. mutant PRDM10 comparison (if studying variant effects)

• Analysis method: Calculate fold enrichment against negative control regions and normalize to input. Consider using both qPCR for targeted analysis and ChIP-seq for genome-wide binding patterns.

These guidelines are based on published protocols that successfully demonstrated PRDM10 binding to the FLCN promoter .

How should I interpret discrepancies between PRDM10 antibody staining patterns in different tissue types?

Discrepancies in PRDM10 staining patterns across tissue types require systematic analysis:

• Antibody specificity assessment:

  • Validate with positive and negative controls (knockout/knockdown tissues or cells)

  • Test multiple antibodies targeting different epitopes to confirm patterns

  • Perform peptide competition assays to confirm specificity

• Technical variations vs. biological differences:

  • Standardize fixation protocols across tissues (overfixation can mask epitopes)

  • Optimize antigen retrieval methods per tissue type

  • Validate findings with orthogonal methods (e.g., RNAscope for mRNA localization)

• Biological interpretation framework:

  • PRDM10 expression varies naturally across tissues due to its tissue-specific roles

  • In soft tissue sarcomas, significant heterogeneity exists, with only 19% of samples showing PRDM10 positivity

  • PRDM10-positive tumors often display distinct morphological features (myxoid changes, multinucleated giant cells)

  • Developmental context matters - expression patterns shift during embryogenesis

• Isoform considerations:

  • Multiple PRDM10 isoforms may exist with different tissue distributions

  • Antibody epitopes may recognize specific isoforms or domains

When reporting discrepancies, present quantitative data on staining intensity, subcellular localization patterns, and percentage of positive cells across different tissue types, and discuss potential biological significance rather than dismissing as technical artifacts.

What are the optimal fixation and antigen retrieval protocols for PRDM10 immunohistochemistry in different tissue types?

Optimization of PRDM10 immunohistochemistry requires tissue-specific protocols:

Fixation protocols:

• For most soft tissues: 10% neutral buffered formalin for 12-24 hours at room temperature

• For brain tissue: 4% paraformaldehyde for 24-48 hours at 4°C

• For embryonic tissues: 4% paraformaldehyde for 6-12 hours (duration dependent on embryonic stage)

Antigen retrieval protocols by tissue type:

Blocking and antibody incubation:

• Use 3-5% BSA in PBS with 0.3% Triton X-100 for blocking (1 hour at room temperature)

• Primary antibody dilution: Begin with 1:100-1:200 for IHC applications

• Incubation: Overnight at 4°C in humid chamber

• Detection system: Polymer-based systems typically provide better signal-to-noise ratio than ABC methods

Always include positive controls (tissues known to express PRDM10) and negative controls (primary antibody omission) in each IHC run.

How can I validate PRDM10 antibody specificity for my specific application?

A comprehensive validation strategy for PRDM10 antibodies should include:

• Genetic validation approaches:

  • CRISPR/Cas9 knockout or knockdown experiments (as performed in the FLCN studies)

  • Overexpression of wildtype and mutant PRDM10 (e.g., doxycycline-inducible systems)

  • Peptide competition assays using the immunizing peptide

• Molecular weight verification:

  • PRDM10's calculated molecular weight is 131 kDa, but observed at 120-150 kDa in Western blots

  • Run positive control lysates (HEK-293 cells show reliable PRDM10 expression)

  • Include size markers and loading controls

• Cross-validation with multiple antibodies:

  • Compare results from antibodies targeting different epitopes (N-terminal, C-terminal, internal domains)

  • Compare monoclonal vs. polyclonal antibodies when possible

• Orthogonal techniques:

  • Correlate protein detection with mRNA expression by qPCR or RNA-seq

  • Verify subcellular localization by immunofluorescence (PRDM10 is predominantly nuclear)

• Application-specific controls:

  • For ChIP: Include IgG control and analyze binding to known PRDM10 target regions

  • For IP: Perform reverse IP when possible

  • For IHC: Include appropriate tissue controls and compare with literature reports

Document all validation steps methodically, as antibody performance can vary significantly between applications, tissue types, and experimental conditions.

What protocol modifications are needed when studying mutant PRDM10 (Cys677Tyr) compared to wildtype PRDM10?

When investigating the PRDM10 Cys677Tyr variant compared to wildtype, several protocol modifications are essential:

• Antibody considerations:

  • Verify that your antibody's epitope does not include or is not affected by the Cys677 residue

  • For antibodies targeting this region, compare binding affinity to both wildtype and mutant proteins

  • Consider using antibodies targeting distant epitopes to minimize detection bias

• Expression level differences:

  • Research shows that mutant PRDM10 Cys677Tyr is expressed at higher levels than wildtype PRDM10

  • Adjust loading controls and antibody dilutions accordingly

  • Consider normalizing to total protein rather than housekeeping genes

• Functional assays:

  • For DNA binding studies (ChIP): The Cys677Tyr variant shows decreased binding to the FLCN promoter

  • Include both positive controls (regions where mutant still binds) and negative controls

  • Extend incubation times for ChIP when studying mutant protein

• Cellular localization:

  • While both wildtype and mutant PRDM10 maintain nuclear localization, subtle differences in subnuclear distribution may exist

  • Use high-resolution imaging (confocal microscopy) with appropriate nuclear markers

• Target gene expression:

  • Include FLCN expression analysis as a validated readout of PRDM10 function

  • Expand to genome-wide expression analysis as mutant PRDM10 affects multiple genes beyond FLCN

• Protein-protein interactions:

  • Adjust IP conditions to account for potential differences in interaction partners

  • Consider BioID or proximity labeling approaches to capture transient interactions

• In vitro transcription assays:

  • For promoter binding studies, include extended incubation times and titration series when testing the mutant protein

These modifications are based on documented differences in expression, binding properties, and downstream effects of the Cys677Tyr variant compared to wildtype PRDM10 .

How can I design experiments to investigate PRDM10's maternal effect on embryonic development?

Designing experiments to study PRDM10's maternal effect requires specialized approaches:

• Genetic models for maternal effect studies:

  • Generate conditional knockout lines (using Zp3-Cre or Gdf9-Cre) to delete PRDM10 specifically in growing oocytes

  • Create rescued lines by introducing wildtype PRDM10 mRNA into PRDM10-deficient oocytes

  • Develop point mutation knockin models to study specific PRDM10 domains

• Developmental timeline analysis:

  • Perform time-lapse imaging of early embryonic divisions (focus on 2-cell stage where arrest occurs)

  • Analyze polar body extrusion and spindle formation in MII oocytes

  • Monitor cytoskeletal dynamics, especially Septin11 localization and complex assembly

• Molecular profiling approaches:

  • Single-cell RNA-seq of PRDM10-deficient vs. control oocytes and early embryos

  • Perform ATAC-seq to assess chromatin accessibility changes

  • ChIP-seq to map PRDM10 binding sites in mature oocytes

• Mechanistic validation experiments:

  • Rescue experiments using microinjection of:

    • Wildtype PRDM10 mRNA

    • Target gene mRNAs (e.g., Septin11)

    • Combinations of multiple targets to assess synergistic effects

  • CRISPR screening to identify additional maternal effect genes in the PRDM10 pathway

• Translational considerations:

  • Compare findings with human oocyte transcriptome datasets

  • Screen for PRDM10 variants in patients with recurrent embryonic arrest

  • Develop non-invasive markers of PRDM10 activity for assessment of oocyte quality

This experimental framework addresses the catastrophic arrest at the 2-cell stage observed in PRDM10-deficient embryos while exploring mechanistic underpinnings through the Septin-complex and other PRDM10 targets .

What approaches can be used to study the relationship between PRDM10 and soft tissue sarcomas?

To investigate PRDM10's role in soft tissue sarcomas, consider these methodological approaches:

• Comprehensive tissue profiling:

  • Establish a tissue microarray of diverse soft tissue sarcoma subtypes

  • Perform multiplex immunohistochemistry for PRDM10 alongside diagnostic markers

  • Quantify PRDM10 expression patterns in relation to myxoid changes and multinucleated giant cells

• Fusion transcript identification and characterization:

  • Design RNA-seq protocols optimized for fusion transcript detection

  • Validate using RT-PCR and Sanger sequencing

  • Characterize functional domains retained in fusion proteins

• Clinicopathological correlation studies:

  • Document associations between PRDM10 expression and surgical margins

  • Track long-term outcomes in PRDM10-positive vs. negative cases

  • Analyze response to therapies based on PRDM10 status

• Functional validation in model systems:

  • Establish patient-derived xenografts from PRDM10-positive tumors

  • Create cell line models expressing PRDM10 fusion proteins

  • Conduct CRISPR-based screens to identify synthetic lethal interactions

• Mechanistic investigations:

  • Perform ChIP-seq to identify direct PRDM10 targets in sarcoma cells

  • Compare transcriptional programs driven by wildtype vs. fusion PRDM10

  • Investigate epigenetic changes (DNA methylation, histone modifications) associated with PRDM10 status

• Therapeutic targeting strategies:

  • Screen small molecule libraries for compounds disrupting PRDM10 binding

  • Test epigenetic modulators in PRDM10-positive vs. negative models

  • Develop PROTAC approaches for PRDM10 degradation

This research framework addresses both diagnostic applications of PRDM10 immunohistochemistry and potential therapeutic implications, building on observations that PRDM10-positive sarcomas display distinct morphological features and surgical outcomes .

How can I integrate ChIP-seq and RNA-seq data to comprehensively map PRDM10's gene regulatory networks?

Integration of ChIP-seq and RNA-seq for mapping PRDM10 regulatory networks requires:

• Experimental design optimization:

  • Perform both assays in the same biological samples when possible

  • Include appropriate controls:

    • Input samples for ChIP-seq

    • PRDM10 knockdown/knockout paired RNA-seq

    • IgG controls for ChIP-seq

  • Consider time-course experiments to capture dynamic changes

• ChIP-seq protocol refinements:

  • Optimize antibody selection for ChIP-grade quality

  • Consider multiple antibodies targeting different PRDM10 domains

  • Use spike-in controls for quantitative comparisons

  • Sequence to sufficient depth (minimum 20 million uniquely mapped reads)

• Bioinformatic integration workflow:

  Analysis Step	Tools	Parameters/Considerations
  ChIP-seq peak calling	MACS2, GEM	q-value < 0.01, fold-enrichment > 4
  Motif discovery	MEME, HOMER	Focus on zinc-finger binding motifs similar to GGTGGTACGGCTCA
  RNA-seq differential expression	DESeq2, edgeR	FDR < 0.05, fold-change > 1.5
  Peak-to-gene assignment	GREAT, ChIPseeker	Test multiple window sizes (5kb, 10kb, 20kb)
  Network construction	Cytoscape, PANDA	Integrate with protein-interaction databases
  Pathway enrichment	GSEA, Enrichr	Custom gene sets from developmental studies

• Validation strategies:

  • Confirm key targets (like FLCN ) using directed ChIP-qPCR and RT-qPCR

  • Perform reporter assays for selected promoters

  • Use CRISPR interference/activation to validate regulatory relationships

  • Investigate specific variants (e.g., Cys677Tyr ) to identify differential binding sites

• Advanced integrative analyses:

  • Incorporate ATAC-seq to assess chromatin accessibility at binding sites

  • Add CUT&RUN for higher resolution binding profiles

  • Consider Hi-C data to identify long-range interactions

  • Integrate with available histone modification data to classify enhancers vs. promoters

This comprehensive approach will help uncover direct and indirect PRDM10 targets, distinguishing between developmental contexts and disease states, while providing mechanistic insights into how PRDM10 regulates genes like FLCN and Septin11 .

What are the most common causes of non-specific bands in PRDM10 Western blots and how can they be resolved?

Non-specific bands in PRDM10 Western blots can arise from several sources:

• Multiple isoform detection:

  • PRDM10 has multiple isoforms that may appear as distinct bands

  • Solution: Verify observed molecular weights against predicted isoform sizes

  • Validate with PRDM10 knockdown/knockout samples to confirm specificity

• Sample preparation issues:

  • Incomplete protein denaturation can cause aggregation or incomplete migration

  • Solution: Extend heating time (95°C for 10 minutes) and increase SDS concentration

  • Add reducing agents fresh before loading

• Proteolytic degradation:

  • PRDM10 (120-150 kDa) may show degradation products

  • Solution: Use fresh protease inhibitor cocktails during lysis

  • Process samples at 4°C and avoid freeze-thaw cycles

• Antibody specificity limitations:

  • Some antibodies may cross-react with other PRDM family members

  • Solution: Test multiple antibodies targeting different epitopes

  • Perform peptide competition assays to confirm specific bands

• Transfer optimization for high molecular weight proteins:

  • PRDM10's size (120-150 kDa) requires optimized transfer conditions

  • Solution: Use lower methanol concentration (10%) in transfer buffer

  • Extend transfer time or use specialized transfer systems for large proteins

• Blocking optimization:

  • Insufficient blocking can increase background

  • Solution: Test alternative blocking agents (5% milk vs. 3-5% BSA)

  • Extend blocking time to 2 hours at room temperature

For troubleshooting non-specific bands, a systematic approach comparing multiple antibodies, positive controls (HEK-293 cells ), and genetic validation samples will help identify true PRDM10 signals.

How can I address the failure to detect PRDM10 in embryonic tissue samples by immunohistochemistry?

Failure to detect PRDM10 in embryonic tissues requires systematic troubleshooting:

• Fixation optimization:

  • Embryonic tissues are sensitive to overfixation

  • Solution: Reduce fixation time (4-8 hours in 4% PFA at 4°C)

  • Consider testing alternative fixatives (e.g., zinc-based fixatives)

• Antigen retrieval enhancement:

  • Embryonic tissues often require gentler but effective retrieval

  • Solution: Test multiple methods in parallel:

    • Citrate buffer (pH 6.0) at 95°C for 10-15 minutes

    • Tris-EDTA (pH 9.0) at 95°C for 10-15 minutes

    • Enzymatic retrieval with proteinase K (1-5 μg/ml for 5-10 minutes)

• Antibody selection and optimization:

  • Not all antibodies perform equally in embryonic tissues

  • Solution: Test antibodies validated in developmental studies

  • Try a range of concentrations (1:50 to 1:500)

  • Extend primary antibody incubation to 48 hours at 4°C

• Signal amplification strategies:

  • PRDM10 expression may be low in certain embryonic stages

  • Solution: Use tyramide signal amplification (TSA)

  • Try polymer-based detection systems with extended development times

• Tissue preparation considerations:

  • Section thickness affects antibody penetration

  • Solution: Use thinner sections (4-5 μm) for paraffin or optimal cutting temperature (OCT) embedded tissues

  • For whole mount staining, extend permeabilization (0.5% Triton X-100 for 1-2 hours)

• Positive control integration:

  • Include tissues with known PRDM10 expression (e.g., neural crest derivatives)

  • Process control tissues alongside experimental samples

If these approaches fail, consider alternative detection methods such as RNAscope for mRNA detection or using reporter mouse models (e.g., PRDM10-GFP) for developmental studies.

What strategies can address inconsistent results in PRDM10 ChIP experiments?

Inconsistent PRDM10 ChIP results can be resolved through these targeted strategies:

• Chromatin preparation optimization:

  • PRDM10 binding to DNA may be sensitive to chromatin preparation methods

  • Solution: Test different cross-linking conditions:

    • Vary formaldehyde concentration (0.5-2%)

    • Test dual cross-linking (DSG followed by formaldehyde)

    • Optimize cross-linking duration (5-20 minutes)

• Sonication parameter refinement:

  • Inadequate or excessive sonication affects chromatin fragmentation

  • Solution: Generate a sonication ladder with different cycle numbers

  • Aim for 200-500 bp fragments

  • Consider enzymatic shearing as an alternative

• Antibody selection and validation:

  • ChIP-grade antibodies are essential

  • Solution: Test multiple antibodies in parallel

  • Validate with PRDM10 overexpression systems

  • Include critical controls (IgG, input, positive loci)

• Cell type consideration:

  • PRDM10 binding patterns vary across cell types

  • Solution: Use cell types with documented PRDM10 expression

  • Consider cell cycle synchronization for binding sites affected by cell cycle

• Buffer optimization:

  • PRDM10-DNA interactions may be sensitive to salt and detergent conditions

  • Solution: Test multiple wash stringencies:

    • Low stringency: 150 mM NaCl

    • Medium stringency: 300 mM NaCl

    • High stringency: 500 mM NaCl

  • Optimize number of washes (4-6 typically)

• PCR optimization for target detection:

  • For ChIP-qPCR, primer design is critical

  • Solution: Design multiple primer sets for each target region

  • Test primer efficiency on input chromatin

  • Use appropriate reference genes for normalization

• Statistical approach:

  • Biological variability in ChIP experiments is common

  • Solution: Perform at least 3-4 biological replicates

  • Use appropriate statistical tests for ChIP-qPCR data

  • For ChIP-seq, ensure sufficient sequencing depth (>20M uniquely mapped reads)

When targeting known PRDM10 binding sites like the FLCN promoter, primer design should focus on the specific binding motif (GGTGGTACGGCTCA) with appropriate controls for regions ~20kb upstream/downstream .